Clinical Trials
13 trialsNCT00641030 2023-06-15
Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes
City of Hope Medical Center
Phase 1 Completed
NCT00498316 2020-02-28
Cord Blood Expansion on Mesenchymal Stem Cells
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00882076 2019-07-24
Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias
Milton S. Hershey Medical Center
Phase 1 Terminated
NCT00295841 2018-08-10
Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Wake Forest University Health Sciences
Phase 1 Completed
NCT01471067 2017-04-28
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00577694 2015-10-12
Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
UNC Lineberger Comprehensive Cancer Center
Phase 1 Terminated
NCT01065545 2015-04-10
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
Northwestern University
Phase 1 Withdrawn
NCT00028418 2015-03-25
Clofarabine in Chronic Lymphocytic Leukemia
FDA Office of Orphan Products Development
Phase 1 Completed
NCT00125840 2014-02-05
Clofarabine in Adult Patients With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT00462787 2013-11-14
Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00081887 2012-08-01
Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00800566 2012-08-01
Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT00293410 2010-05-06
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed